On March 8, 2022 Phost’in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, reported TechShare 2022, the pan-European pre-IPO educational program of Euronext. For the 7th year, Euronext is renewing its annual support program for growing European Tech companies (digital, cleantech and healthcare) aiming to go public (Press release, Phost’in, MAR 8, 2022, View Source [SID1234609655]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year, more than 120 companies will join the program, including 40 from France, but also 9 other European countries: Germany, Belgium, Spain, France, Ireland, Italy, Norway, Netherlands, Portugal and Switzerland.
Phost’in Therapeutics was selected after a selection process and a presentation to the final jury composed of representatives of TechShare’s Selection partners* in France.
As a participant of the TechShare program, Phost’in Therapeutics will benefit from support of market experts and already quoted peers to understand the motivations and mechanisms of an IPO. Through a structured training around an academic campus, workshops and individual sessions, participants will be trained in the steps and challenges of an IPO, the building of an equity story and of a company valuation, understanding investors’ expectations, good practices in financial communication, corporate governance and post-quotation obligations. The cornerstone of the program is to promote networking and experience sharing between participating entrepreneurs, financial market experts and managers of quoted companies.
With more than 750 Tech companies quoted on our markets, Euronext is the leading quotation place for Tech companies in Europe. In 2021, Euronext recorded an ever set high record of 212 listings, with more than 50% of companies from the Tech sector. Euronext Paris hosted a record of 64 quotations in 2021 for nearly 4 billion euros raised, including 54 SMEs-ETIs. Since its launch in 2015, TechShare has welcomed nearly 170 Alumni in France. 10 of these French companies completed an IPO, 6 of them in less than a year, illustrating the market dynamics and growing maturity of the TechShare community.
Karine Chorro, CEO of Phost’in Therapeutics, said: "We are proud of this selection, and thrilled to take advantage of this opportunity to discuss with quoted companies and the best experts in the ecosystem. This experience should help us to prepare and select the best solutions to ensure our growth, and consolidate our position as a European leader in the Glyco-Immuno-Oncology field, as our first program, the First-In-Class Phox430 is enterin clinical steps. »
The TechShare 2022 program is also supported by the following institutional partners: AFPC (Association Française des Pôles de Compétitivité, i.e. French association of competitiveness clusters), Bpifrance, CroissancePlus, France Biotech, FranceDigitale, France Fintech, France Invest, GreenUnivers, La French Tech, Réseau PEXE, The Galion Project, WILLA.